Federated Hermes Inc. Increases Holdings in Veeva Systems Inc. $VEEV

Federated Hermes Inc. increased its position in Veeva Systems Inc. (NYSE:VEEV) by 55.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 685,261 shares of the technology company’s stock after buying an additional 244,419 shares during the quarter. Federated Hermes Inc. owned 0.42% of Veeva Systems worth $204,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Sigma Planning Corp lifted its holdings in shares of Veeva Systems by 1.2% in the 2nd quarter. Sigma Planning Corp now owns 3,328 shares of the technology company’s stock worth $958,000 after acquiring an additional 39 shares during the last quarter. Private Trust Co. NA raised its position in Veeva Systems by 17.1% in the 3rd quarter. Private Trust Co. NA now owns 281 shares of the technology company’s stock worth $84,000 after purchasing an additional 41 shares during the period. Keybank National Association OH lifted its stake in Veeva Systems by 1.4% in the second quarter. Keybank National Association OH now owns 3,088 shares of the technology company’s stock worth $889,000 after purchasing an additional 42 shares during the last quarter. Baron Wealth Management LLC boosted its position in Veeva Systems by 1.7% during the third quarter. Baron Wealth Management LLC now owns 2,447 shares of the technology company’s stock valued at $729,000 after buying an additional 42 shares during the period. Finally, Apollon Wealth Management LLC grew its stake in shares of Veeva Systems by 1.5% during the third quarter. Apollon Wealth Management LLC now owns 2,905 shares of the technology company’s stock valued at $865,000 after buying an additional 42 shares during the last quarter. 88.20% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on VEEV shares. Wells Fargo & Company lowered their target price on Veeva Systems from $341.00 to $333.00 and set an “overweight” rating for the company in a research note on Tuesday, November 25th. KeyCorp reaffirmed a “sector weight” rating on shares of Veeva Systems in a research note on Friday, December 12th. Canaccord Genuity Group reissued a “buy” rating on shares of Veeva Systems in a research note on Tuesday, November 25th. The Goldman Sachs Group assumed coverage on shares of Veeva Systems in a report on Tuesday, January 13th. They issued a “sell” rating and a $215.00 target price on the stock. Finally, Robert W. Baird upped their price target on shares of Veeva Systems from $314.00 to $319.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Eighteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $308.04.

Insider Buying and Selling

In other Veeva Systems news, insider Thomas D. Schwenger sold 1,000 shares of Veeva Systems stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $231.43, for a total transaction of $231,430.00. Following the sale, the insider directly owned 23,204 shares of the company’s stock, valued at approximately $5,370,101.72. The trade was a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.30% of the stock is owned by company insiders.

Veeva Systems Stock Down 2.9%

Shares of Veeva Systems stock opened at $217.71 on Wednesday. The business has a 50 day moving average of $230.39 and a 200 day moving average of $265.99. Veeva Systems Inc. has a 52 week low of $201.54 and a 52 week high of $310.50. The company has a market cap of $35.79 billion, a PE ratio of 42.36, a P/E/G ratio of 1.66 and a beta of 1.07.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Thursday, November 20th. The technology company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.95 by $0.09. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The business had revenue of $0.81 million for the quarter, compared to analysts’ expectations of $792.37 million. During the same quarter in the previous year, the business posted $1.75 earnings per share. The firm’s revenue for the quarter was up 16.0% compared to the same quarter last year. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. On average, research analysts anticipate that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Veeva Systems announced that its Board of Directors has authorized a stock buyback program on Monday, January 5th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the technology company to purchase up to 5.5% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.